Oncolytics Biotech (TSE:ONC) Director Bernd Robert Seizinger Buys 40,000 Shares

Oncolytics Biotech Inc. (TSE:ONC) Director Bernd Robert Seizinger bought 40,000 shares of the stock in a transaction on Thursday, February 12th. The shares were bought at an average price of C$1.17 per share, with a total value of C$46,800.00. Following the acquisition, the director owned 566,991 shares of the company’s stock, valued at C$663,379.47. This trade represents a 7.59% increase in their ownership of the stock.

Bernd Robert Seizinger also recently made the following trade(s):

• On Wednesday, February 11th, Bernd Robert Seizinger purchased 60,000 shares of Oncolytics Biotech stock. The stock was bought at an average price of C$1.14 per share, for a total transaction of C$68,400.00.

Oncolytics Biotech Trading Down 1.3%

ONC opened at C$14.90 on Friday. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. Oncolytics Biotech Inc. has a 12 month low of C$0.44 and a 12 month high of C$2.08. The stock has a fifty day moving average price of C$14.90 and a 200-day moving average price of C$13.03.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. As a group, equities research analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.